Consolidation therapy without maintenance for acute non-lymphoblastic leukaemia. 1988

M M Roberts, and C A Juttner, and R W Blunden, and N Horvath, and L B To, and J Q Ho, and G W Dart, and R J Kimber
Division of Haematology, Institute of Medical and Veterinary Science, Adelaide, SA.

The most effective therapy to prolong remission and to increase cure rates in patients with acute non-lymphoblastic leukaemia is uncertain, and approaches vary from one course of consolidation to two years of maintenance and intensification therapy. We report the results of brief intensive therapy with daunorubicin, cytosine arabinoside and thioguanine, and no maintenance therapy, in 72 patients with a minimum follow-up period of two years. The complete remission rate was 67%, the median duration of remission was 11 months, and 23% of patients whose leukaemias went into remission, have remained in remission for three years and longer. These results are equivalent to those that have been reported with long-term chemotherapy.

UI MeSH Term Description Entries
D007938 Leukemia A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006) Leucocythaemia,Leucocythemia,Leucocythaemias,Leucocythemias,Leukemias
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D003561 Cytarabine A pyrimidine nucleoside analog that is used mainly in the treatment of leukemia, especially acute non-lymphoblastic leukemia. Cytarabine is an antimetabolite antineoplastic agent that inhibits the synthesis of DNA. Its actions are specific for the S phase of the cell cycle. It also has antiviral and immunosuppressant properties. (From Martindale, The Extra Pharmacopoeia, 30th ed, p472) Ara-C,Arabinofuranosylcytosine,Arabinosylcytosine,Cytosine Arabinoside,Aracytidine,Aracytine,Cytarabine Hydrochloride,Cytonal,Cytosar,Cytosar-U,beta-Ara C,Ara C,Arabinoside, Cytosine,Cytosar U,beta Ara C
D003630 Daunorubicin A very toxic anthracycline aminoglycoside antineoplastic isolated from Streptomyces peucetius and others, used in treatment of LEUKEMIA and other NEOPLASMS. Daunomycin,Rubidomycin,Rubomycin,Cerubidine,Dauno-Rubidomycine,Daunoblastin,Daunoblastine,Daunorubicin Hydrochloride,NSC-82151,Dauno Rubidomycine,Hydrochloride, Daunorubicin,NSC 82151,NSC82151
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

M M Roberts, and C A Juttner, and R W Blunden, and N Horvath, and L B To, and J Q Ho, and G W Dart, and R J Kimber
August 1986, Lancet (London, England),
M M Roberts, and C A Juttner, and R W Blunden, and N Horvath, and L B To, and J Q Ho, and G W Dart, and R J Kimber
January 1991, European journal of cancer (Oxford, England : 1990),
M M Roberts, and C A Juttner, and R W Blunden, and N Horvath, and L B To, and J Q Ho, and G W Dart, and R J Kimber
September 1982, Archives of disease in childhood,
M M Roberts, and C A Juttner, and R W Blunden, and N Horvath, and L B To, and J Q Ho, and G W Dart, and R J Kimber
May 1994, British journal of haematology,
M M Roberts, and C A Juttner, and R W Blunden, and N Horvath, and L B To, and J Q Ho, and G W Dart, and R J Kimber
April 2013, European journal of haematology,
M M Roberts, and C A Juttner, and R W Blunden, and N Horvath, and L B To, and J Q Ho, and G W Dart, and R J Kimber
July 2016, The Lancet. Oncology,
M M Roberts, and C A Juttner, and R W Blunden, and N Horvath, and L B To, and J Q Ho, and G W Dart, and R J Kimber
September 1985, Indian journal of cancer,
M M Roberts, and C A Juttner, and R W Blunden, and N Horvath, and L B To, and J Q Ho, and G W Dart, and R J Kimber
December 2019, Scientific reports,
M M Roberts, and C A Juttner, and R W Blunden, and N Horvath, and L B To, and J Q Ho, and G W Dart, and R J Kimber
January 1987, Archives of disease in childhood,
M M Roberts, and C A Juttner, and R W Blunden, and N Horvath, and L B To, and J Q Ho, and G W Dart, and R J Kimber
May 1986, Lancet (London, England),
Copied contents to your clipboard!